Nanosphere cleared to include H1N1 info on flu test label
This article was originally published in Clinica
Nanosphere can now include claims of H1N1 virus detection in the package insert for its respiratory syncytial virus test on the Verigene SP system. The US FDA has granted a 510(k) clearance for the firm to include data on "reactivity with influenza A in cultured clinical isolates containing 2009 H1N1 influenza virus". The RT-PCR-based test can correctly identify influenza A in samples containing this year's H1N1 virus, but cannot identify flu subtypes (such as H1N1). The performance of the assay with specimens positive for H1N1 has not been established, Nanosphere (Northbrook, Illinois) conceded. The test was cleared on the firm's next-generation system in October (www.clinica.co.uk, October 15 2009).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.